CURE

FDA Approves PD-L1 Test to Guide Keytruda Use in Esophageal and GEJ Cancer

FDA approves a PD-L1 test to help identify patients with esophageal or gastroesophageal junction (GEJ) cancer who may benefit ...
Business Wire

CAP Publishes Guideline for PD-L1 Testing of Patients with Lung Cancer

NORTHFIELD, Ill.--(BUSINESS WIRE)--The College of American Pathologists (CAP) in collaboration with the International Association for the Study of Lung Cancer (IASLC), Pulmonary Pathology Society (PPS ...
Targeted Oncology

Precision or Urgency? Managing PD-L1 Testing in Metastatic NSCLC

Experts review a stage IV NSCLC case, debating whether to delay treatment while awaiting PD-L1 results to ensure a more ...
News Medical

Value of PD-L1 testing in NSCLC debated

Two viewpoint articles published in JAMA Oncology provide opposing opinions on the benefit of testing for programmed death-ligand 1 (PD-L1) expression in patients with non-small-cell lung cancer ...
ascopubs.org

TAPping Into PD-L1 Testing Efficiency for Gastroesophageal Cancer

Consistently, first-line trials of immune checkpoint inhibitors in combination with chemotherapy have demonstrated overall survival benefit for patients with metastatic gastroesophageal cancer.
Health And Pharma

FDA Approves Agilent’s PD-L1 Test to Guide KEYTRUDA Use in Esophageal and GEJ Carcinoma

Agilent has received FDA approval for PD-L1 IHC 22C3 pharmDx, Code SK006, as a companion diagnostic to identify patients with esophageal or gastroesophageal junction carcinoma eligible for ...